Brentuximab Vedotin (Genetical Recombination) for I.V. Infusion 50mg (Adcetris® / アドセトリス点滴静注用50mg)

JPY ¥486,200

Japanese antineoplastic agent / anti-CD30 monoclonal antibody conjugated with microtubule inhibitor (Brentuximab Vedotin 50mg). For intravenous infusion in CD30-positive Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, and relapsed or refractory Cutaneous T-Cell Lymphoma. 1 vial. Mfd. by Takeda Pharmaceutical Company Limited, Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥447,304
10 - 19 12% JPY ¥427,856
20 + 18% JPY ¥398,684
SKU: ADC-50-INJ Category:

Description

Product Overview / 商品概要

Adcetris for I.V. Infusion 50mg (アドセトリス点滴静注用50mg)
Generic: Brentuximab Vedotin (Genetical Recombination) / ブレンツキシマブ ベドチン(遺伝子組換え)
Therapeutic Category: Antineoplastic Agent / Anti-CD30 Monoclonal Antibody Conjugated with Microtubule Inhibitor / 抗悪性腫瘍剤/微小管阻害薬結合抗CD30 モノクローナル抗体
Manufactured by: Takeda Pharmaceutical Company Limited / 武田薬品工業株式会社

Composition & Specification / 組成・規格

Active Ingredient: Brentuximab Vedotin (Genetical Recombination) 55mg per vial (overfilled; yields 5mg/mL when reconstituted with 10.5mL, providing 50mg deliverable dose) / 1バイアル中 ブレンツキシマブ ベドチン(遺伝子組換え)55mg(過量充填、10.5mLで溶解時に5mg/mLとなる)
Additives: Trehalose hydrate 770mg, Citric acid hydrate 2.3mg, Sodium citrate hydrate 61.7mg, Polysorbate 80 2.2mg / トレハロース水和物 770mg、クエン酸水和物 2.3mg、クエン酸ナトリウム水和物 61.7mg、ポリソルベート80 2.2mg
Appearance: White to off-white cake or powder (lyophilized formulation); pH approximately 6.6 (upon reconstitution with 10.5mL Japanese Pharmacopoeia Water for Injection); osmolarity ratio approximately 1 (relative to JP normal saline, upon reconstitution with 10.5mL JP Water for Injection)
外観: 白色~灰白色の塊又は粉末(凍結乾燥製剤)、pH 約6.6(日局注射用水10.5mLにて溶解時)、浸透圧比 約1(日局生理食塩液に対する比、日局注射用水10.5mLにて溶解時)

Indications / 効能効果

EN: CD30-positive diseases: Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Relapsed or Refractory Cutaneous T-Cell Lymphoma
JA: CD30陽性の下記疾患:ホジキンリンパ腫、末梢性T細胞リンパ腫、再発又は難治性の皮膚T細胞リンパ腫

Dosage and Administration / 用法用量

EN: In combination with doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine: administer once every 2 weeks up to a maximum of 12 infusions. Dose: Adults 1.2mg/kg body weight; Pediatric patients 48mg/m2 body surface area. Reduce dose as appropriate based on patient condition. In combination with cyclophosphamide hydrate, doxorubicin hydrochloride, and prednisolone: administer 1.8mg/kg body weight once every 3 weeks up to a maximum of 8 infusions in adults. Reduce dose as appropriate. Administer 1.8mg/kg body weight once every 3 weeks by intravenous infusion. Reduce dose as appropriate. Administer 1.8mg/kg body weight once every 3 weeks by intravenous infusion in adults. Reduce dose as appropriate.
JA: 〈未治療のCD30陽性のホジキンリンパ腫〉ドキソルビシン塩酸塩、ビンブラスチン硫酸塩及びダカルバジンとの併用において、通常、ブレンツキシマブ ベドチン(遺伝子組換え)として以下の用量を2週間に1回、最大12回点滴静注する。なお、患者の状態に応じて適宜減量する。成人には、1回1.2mg/kg(体重)、小児には、1回48mg/m2(体表面積)。〈未治療のCD30陽性の末梢性T細胞リンパ腫〉シクロホスファミド水和物、ドキソルビシン塩酸塩及びプレドニゾロンとの併用において、通常、成人には、3週間に1回1.8mg/kg(体重)を最大8回点滴静注する。なお、患者の状態に応じて適宜減量する。〈再発又は難治性のCD30陽性のホジキンリンパ腫及び末梢性T細胞リンパ腫〉通常、3週間に1回1.8mg/kg(体重)を点滴静注する。なお、患者の状態に応じて適宜減量する。〈再発又は難治性のCD30陽性の皮膚T細胞リンパ腫〉通常、成人には、3週間に1回1.8mg/kg(体重)を点滴静注する。なお、患者の状態に応じて適宜減量する。

Contraindications / 禁忌

EN: 2.1 Patients with a history of severe hypersensitivity to any component of this product. 2.2 Patients currently receiving bleomycin hydrochloride.
JA: 2.1 本剤の成分に対し重度の過敏症の既往歴のある患者。2.2 ブレオマイシン塩酸塩を投与中の患者。

Regulatory Information / 規制情報

Approval No.: 22600AMX00031
Sales Started: April 2014 / 2014年4月
Classification Code: 874291
Storage: Store at 2-8°C, avoid freezing. Store protected from light after opening the outer carton. / 凍結を避け、2~8℃で保存。個装箱開封後は遮光保存すること。
Shelf Life: 4 years / 4年

Packaging / 包装

Main Package (for sale): 1 vial / 1バイアル
Other Available Packages (by special order): 1 vial

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Brentuximab Vedotin (Genetical Recombination) for I.V. Infusion 50mg (Adcetris® / アドセトリス点滴静注用50mg)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Brentuximab Vedotin (Genetical Recombination) for I.V. Infusion 50mg (Adcetris®

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.